RxDoctor Payments Data

Kim McCoy

Nurse Practitioner · Melrose Park, ILNPI 1568858223

Payments from drug & device makers

$4,532in general payments, 2019–2025

Across 123 payments — averaging $36.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$864
  • Merz North America, Inc.$528
  • E.r. Squibb & Sons, L.L.C.$376
  • Lundbeck LLC$200
  • AbbVie$179
  • plus $529 from 9 others

What the payments were for

  • Food & beverage$4,31895%
  • Education$2135%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,532 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$6,256
Medicare patients
17
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate38$129,362
Paliperidone ErPaliperidone17$4,436
Guanfacine Hcl18$1,248
Quetiapine Fumarate37$1,060
Fluvoxamine Maleate11$952
Olanzapine35$930
Aripiprazole13$735
Trazodone Hcl46$697
Haloperidol Decanoate22$568
LoxapineLoxapine Succinate17$560
Fluphenazine Hcl17$532
Benztropine Mesylate30$428
Doxepin Hcl15$384
Hydroxyzine Hcl25$349
Duloxetine Hcl13$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,855$129,36238 claims
Teva Pharmaceuticals USA, Inc.Loxapine$37$56017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Melrose Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →